Evidence map›Paper›PMID 37335995›Full record

SynthesisThe Cochrane database of systematic reviews2023

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.

Annika Theodoulou, Samantha C Chepkin, Weiyu Ye, Thomas R Fanshawe, Chris Bullen, Jamie Hartmann-Boyce, Jonathan Livingstone-Banks, Anisa Hajizadeh, Nicola Lindson

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 7 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 7 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2025
    Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Characteristics of Black Adults Who Never Achieved 24-Hours of Abstinence in a Smoking Cessation Trial: Implications for Improving Treatment Response.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Trial
  10. Trial
  11. Effectiveness of Nicotine Replacement Therapy and Behavioral Intervention in Tobacco Cessation-A Tertiary Hospital-Based Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Mixed Methods Process Evaluation of Behavioral Support and Nicotine Replacement Therapy for Smokeless Tobacco Cessation in Bangladesh, India, and Pakistan.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Annika TheodoulouNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Samantha C ChepkinNHS Hertfordshire and West Essex Integrated Care Board, Welwyn Garden City, UK.
Weiyu YeOxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.
Thomas R FanshaweNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Chris BullenNational Institute for Health Innovation, University of Auckland, Auckland, New Zealand.
Jamie Hartmann-BoyceNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Jonathan Livingstone-BanksNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Anisa HajizadehNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Nicola LindsonNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
University of Oxford · GBAuckland University of Technology · NZHertfordshire Community NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNicotine replacement therapy (NRT) aims to replace nicotine from cigarettes. This helps to reduce cravings and withdrawal symptoms, and ease the transition from cigarette smoking to complete abstinence. Although there is high-certainty evidence that NRT is effective for achieving long-term smoking abstinence, it is unclear whether different forms, doses, durations of treatment or timing of use impacts its effects.

objectivesTo determine the effectiveness and safety of different forms, deliveries, doses, durations and schedules of NRT, for achieving long-term smoking cessation. SEARCH

methodsWe searched the Cochrane Tobacco Addiction Group trials register for papers mentioning NRT in the title, abstract or keywords, most recently in April 2022. SELECTION CRITERIA: We included randomised trials in people motivated to quit, comparing one type of NRT use with another. We excluded studies that did not assess cessation as an outcome, with follow-up of fewer than six months, and with additional intervention components not matched between arms. Separate reviews cover studies comparing NRT to control, or to other pharmacotherapies. DATA COLLECTION AND ANALYSIS: We followed standard Cochrane methods. We measured smoking abstinence after at least six months, using the most rigorous definition available. We extracted data on cardiac adverse events (AEs), serious adverse events (SAEs) and study withdrawals due to treatment.  MAIN

resultsWe identified 68 completed studies with 43,327 participants, five of which are new to this update. Most completed studies recruited adults either from the community or from healthcare clinics. We judged 28 of the 68 studies to be at high risk of bias. Restricting the analysis only to those studies at low or unclear risk of bias did not significantly alter results for any comparisons apart from the preloading comparison, which tested the effect of using NRT prior to quit day whilst still smoking.  There is high-certainty evidence that combination NRT (fast-acting form plus patch) results in higher long-term quit rates than single form (risk ratio (RR) 1.27, 95% confidence interval (CI) 1.17 to 1.37; I AUTHORS'

conclusionsThere is high-certainty evidence that using combination NRT versus single-form NRT and 4 mg versus 2 mg nicotine gum can result in an increase in the chances of successfully stopping smoking. Due to imprecision, evidence was of moderate certainty for patch dose comparisons. There is some indication that the lower-dose nicotine patches and gum may be less effective than higher-dose products. Using a fast-acting form of NRT, such as gum or lozenge, resulted in similar quit rates to nicotine patches. There is moderate-certainty evidence that using NRT before quitting may improve quit rates versus using it from quit date only; however, further research is needed to ensure the robustness of this finding. Evidence for the comparative safety and tolerability of different types of NRT use is limited. New studies should ensure that AEs, SAEs and withdrawals due to treatment are reported.

Indexed as

Smoking CessationDelivery of Health CareHumansNicotineNicotinic AgonistsTobacco Use Cessation DevicesNicotineNicotinic Agonists

Identifiers

PMID37335995
PMCPMC10278922
OpenAlexW4381144745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.